Total permanent disability insurance

Guardian Angels Medical Service Dogs to Break Ground on Pennsylvania Campus

Retrieved on: 
Tuesday, November 7, 2023
Weather, Montour Trail, Government, Total permanent disability insurance, Diabetes, National anthem, Dog, RSVP, PTSD, Seizure, Mobility, Community project, Pleasure, Colour guard, Bethany Presbyterian Church, Hospital, Traumatic brain injury, Borden Institute, Borden, Pharmaceutical industry, Nightclub

Pittsburgh, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Guardian Angels Medical Service Dogs has announced they are breaking ground on their Pennsylvania Campus.

Key Points: 
  • Pittsburgh, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Guardian Angels Medical Service Dogs has announced they are breaking ground on their Pennsylvania Campus.
  • Guardian Angels Medical Service Dogs is a 501(c)3 organization based in Williston, Florida.
  • Congressman Reschenthaler worked to help Guardian Angels Medical Service Dogs acquire $3 million in Community Project Funding for the campus.
  • To learn more about this event or how to support this project by purchasing a brick, sponsoring a building, or donating, visit the Guardian Angels Medical Service Dogs website at medicalservicedogs.org.

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Retrieved on: 
Wednesday, October 11, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, HIV disease progression rates, COVID-19, RMS, Bristol Myers Squibb, NYSE, Quality of life, EDSS, Brain, Circulatory system, Multiple sclerosis, Interim, Disease, Barrow Neurological Institute, Month, CDP, Total permanent disability insurance, Literature, Head, RAW, Overalls, PIRA, BMY, Patient, Cleveland Clinic, Pharmaceutical industry, MD, SDMT, Ozanimod, Immunology

Bristol Myers Squibb (NYSE: BMY) today announced new data showing that after eight years of follow-up, 76% of patients treated with Zeposia for relapsing multiple sclerosis (RMS) were free of six-month confirmed disability progression (CDP).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced new data showing that after eight years of follow-up, 76% of patients treated with Zeposia for relapsing multiple sclerosis (RMS) were free of six-month confirmed disability progression (CDP).
  • Findings also demonstrated treatment with Zeposia resulted in low rates of progression independent relapse activity (PIRA) and relapse-associated worsening (RAW), key drivers of disease progression and permanent disability in multiple sclerosis.
  • “These new data underscore Zeposia’s potential to delay disease progression and improve cognitive function, especially in individuals with early relapsing multiple sclerosis,” said Roland Chen, MD , senior vice president and head, Immunology, Cardiovascular and Neuroscience Development, Bristol Myers Squibb.
  • “With our focus on transformational science, we remain deeply committed to finding solutions to elevate care for the multiple sclerosis community.”
    Bristol Myers Squibb thanks the patients and investigators who participated in the Zeposia clinical trials.

GENXFINANCIAL'S SUCCESSION PLANNING PLATFORM SOLVES SUCCESSION PLANNING CHALLENGES FOR SOLO ADVISORS

Retrieved on: 
Thursday, September 21, 2023
Total permanent disability insurance, Partnership, Death, Succession, Family, Selling My Soul, Financial adviser

NASHVILLE, Tenn., Sept. 21, 2023 /PRNewswire/ -- GenXFinancial is making waves in the independent advisor space with its SellMyFinancialPractice platform. Since its launch in 2021, the platform has assisted over 50 solo advisors with continuity plans and has implemented 15 succession plans. The platform especially appeals to solo advisors nearing retirement without a continuity and succession partner. 

Key Points: 
  • Since its launch in 2021, the platform has assisted over 50 solo advisors with continuity plans and has implemented 15 succession plans.
  • The platform especially appeals to solo advisors nearing retirement without a continuity and succession partner.
  • The platform offers turnkey continuity and succession solutions for advisors in the independent space.
  • "GenXFinancial has been able to leverage Osaic's industry leading advisor M&A and continuity planning resources," said Todd Fulks, SVP Advisor M&A and Succession.

Partners Life Launches Medical Claims on the FINEOS Platform

Retrieved on: 
Tuesday, September 5, 2023
Professional Services, Technology, Insurance, Software, Human Resources, Partners Life, FINEOS, Case management (US healthcare system), LISA, TPD, Total permanent disability insurance, Trauma, Life insurance, Health insurance

Partners Life, one of New Zealand’s largest private life and health insurance companies, has become the first insurer to successfully launch medical claims on the FINEOS Platform, as outlined in a new case study .

Key Points: 
  • Partners Life, one of New Zealand’s largest private life and health insurance companies, has become the first insurer to successfully launch medical claims on the FINEOS Platform, as outlined in a new case study .
  • The move to the cloud-native purpose-built FINEOS Platform enables Partners Life to provide enhanced claims processing, reduced claims leakage, and streamlined user experience to 300,000 Kiwis.
  • Early last year, Partners Life became the first life insurance company in New Zealand to go live on the FINEOS Platform, replacing its legacy system with FINEOS Claims for life, total and permanent disability (TPD), trauma and income protection.
  • The second phase of the project, completed this year, brought the component-based capabilities of FINEOS AdminSuite to medical claims at Partners Life through the market-tested, preconfigured FINEOS Life Insurance Solution Australasia (LISA).

Inherent Risks Launches Ukraine Medical and Crisis Response Membership

Retrieved on: 
Thursday, August 24, 2023
Volunteering, Insurance, Medicine, Risk, Medical evacuation, Travel, Inherent risk, Intelligence, Non-governmental organization, Total permanent disability insurance, Death, Lloyd's of London, Tourism

London, United Kingdom--(Newsfile Corp. - August 24, 2023) - Global risk advisory, Inherent Risks, has launched an agile Medical Evacuation and Crisis Response Membership enabling individuals and groups to safely (re)enter Ukraine, and (re)establish operations.

Key Points: 
  • London, United Kingdom--(Newsfile Corp. - August 24, 2023) - Global risk advisory, Inherent Risks, has launched an agile Medical Evacuation and Crisis Response Membership enabling individuals and groups to safely (re)enter Ukraine, and (re)establish operations.
  • To satisfy minimum sum amounts required by global duty of care guidelines, its Medical Response Membership exceeds these by offering $250,000 USD of medical services, including bill payment for medical treatment in Ukraine, medical evacuation from Ukraine, and repatriation home.
  • Crisis Response Membership offers $150,000 USD of crisis services in the event of a credible security incident or threat against an individual or organisation.
  • Inherent Risks has had a continued presence in Ukraine since February 2022, providing risk advisory, intelligence, medical evacuation and crisis response services to insurance companies, non-governmental organisations (NGOs), global media agencies, war crimes investigators, HNWIs, visiting dignitaries; and on behalf of international assistance companies.

Despite Last Minute Change, UnitedHealthcare's Policy for Virtually All Colonoscopies and Endoscopies Lays Groundwork for Delays, Disruptions, and Denials of Life-saving Services

Retrieved on: 
Thursday, June 1, 2023
Insurance, American Gastroenterological Association, Gold card, Face, Hospital, G.I., Policy, Endoscopy, American Medical Association, Organization, Incidence, CO, AGAF, AGA, HIV disease progression rates, Patient, Collection, UnitedHealth Group, Risk, Colorectal cancer, Physician, Cancer, AMA, UHC, Diagnosis, Total permanent disability insurance, Research, Health, GI, Death, Polyp, Health insurance, Medical device, Pharmaceutical industry, Nursing, MD, United

WASHINGTON, June 1, 2023 /PRNewswire/ -- While the American Gastroenterological Association (AGA) accepts that UnitedHealthcare (UHC) backed off its disastrous decision to begin imposing prior authorization on gastroenterology endoscopy services for all commercial plans starting June 1, AGA remains extremely concerned that the advance notification program UHC is rolling out instead is a temporary patch likely to have significant repercussions for patient access in the coming months. UHC's advance notification program, hastily announced to reporters late yesterday, only temporarily postpones prior authorization requirements set to impact the insurance giant's 27 million commercial beneficiaries while increasing the administrative burden on providers. Clear to the AGA from discussions last Friday, UHC does not currently have data demonstrating any significant overutilization of critical endoscopy and colonoscopy procedures that would justify this program or prior authorization. Since colorectal cancer is the #2 cancer killer and rates are rising in younger adults, now is not the time to increase barriers for patients who need GI care.

Key Points: 
  • The nebulous advance notification program UHC announced late last night will impact virtually all endoscopies and colonoscopies for UHC's commercial plans.
  • The poorly defined "advance notification program" would ostensibly require physician practices to input copious amounts of highly complex and granular patient data prior to performing colonoscopies and endoscopies.
  • These services are critical for the early diagnosis of life-threatening diseases such as colorectal cancer and for monitoring patients' disease progression.
  • This new policy comes despite immense pressure from physicians, patients, lawmakers, and regulators to crack down on abusive prior authorization policies.

Super Woman Super Lawyer Wins $27M for Motorcycle Accident Victim

Retrieved on: 
Wednesday, May 3, 2023
Total permanent disability insurance, Insurance, Policy, Male, Woman, Multimedia, Practice of law

NEWPORT BEACH, Calif., May 3, 2023 /PRNewswire/ -- In a remarkable legal victory, distinguished and determined attorney, Super Woman Super Lawyer Maryam Parman and her team won a staggering $27,000,000 for a motorcycle accident victim in an unincorporated area of Orange County.

Key Points: 
  • NEWPORT BEACH, Calif., May 3, 2023 /PRNewswire/ -- In a remarkable legal victory, distinguished and determined attorney, Super Woman Super Lawyer Maryam Parman and her team won a staggering $27,000,000 for a motorcycle accident victim in an unincorporated area of Orange County.
  • Despite the case's complexity, Super Woman Super Lawyer's team fought tirelessly on behalf of their client, refusing to settle for anything less than what he deserved.
  • Super Woman Super Lawyer secured a settlement exceeding the insurance policy limit of $50,000, providing her client with the financial support to compensate for numerous medical bills and lost wages.
  • Super Woman Super Lawyer has earned a reputation as one of the most skilled and tenacious attorneys in the country, and this case only adds to her impressive track record.

TIME IS RUNNING OUT: Patients, Physicians Brace for Anticipated Delays, Denials by UnitedHealthcare for Endoscopies Starting 6/1

Retrieved on: 
Monday, May 1, 2023
Insurance, Education, Health, Hospital, Anxiety, Policy, Cancer, American Gastroenterological Association, Private practice, American Medical Association, AGA, HIV disease progression rates, MD, Patient, Physician, UnitedHealth Group, Colorectal cancer, AMA, UHC, Diagnosis, Nursing care plan, Total permanent disability insurance, GI, Death, Safety, Nursing, Health insurance

WASHINGTON, May 1, 2023 /PRNewswire/ -- The American Gastroenterological Association (AGA) is profoundly alarmed and disappointed by UnitedHealthcare's (UHC) recently announced prior authorization requirement for gastroenterology endoscopy services for all commercial plans, regardless of the outpatient location. Despite recently trumpeting its decision to cut down on its use of prior authorization, UnitedHealthcare's expansion of prior authorization for most physician-prescribed endoscopy procedures—effective June 1—could disrupt time-sensitive care for millions of patients and create needless anxiety and delays for patients who may have cancer or other serious gastrointestinal conditions.

Key Points: 
  • UHC's new prior authorization policy will impact esophagogastroduodenoscopies, capsule endoscopies, diagnostic colonoscopies, and surveillance colonoscopies.
  • These services are critical for the early diagnosis of life-threatening diseases such as colorectal cancer and for monitoring patients' disease progression.
  • This new policy comes despite immense pressure from physicians, patients, lawmakers, and regulators to crack down on abusive prior authorization policies.
  • In fact, 46% of physicians report that prior authorization has led to immediate care and/or emergency room visits.

Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases

Retrieved on: 
Tuesday, February 28, 2023
Spectrum disorder, Total permanent disability insurance, Collection, Disease, Self-assessment, Biomarker, Research, Algorithm, Patient, Rare disease, Digital, GMG, Fatigue, Alexion, Communication, Pharmaceutical industry, Medical imaging, NMOSD, Neurology

The programs will leverage assets, methodologies and expertise built by Ad Scientiam over the past five years and are supported by Alexion, AstraZeneca Rare Disease.

Key Points: 
  • The programs will leverage assets, methodologies and expertise built by Ad Scientiam over the past five years and are supported by Alexion, AstraZeneca Rare Disease.
  • gMG and NMOSD are chronic severe diseases in which progression is complex and critical to monitor.
  • Digital biomarkers are patient-generated physiological and behavioral measures that are collected from digital devices like smartphones and processed by algorithms.
  • Scoping phases have been conducted for both programs to identify clinically meaningful digital biomarkers to monitor patients living with NMOSD or gMG.

Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases

Retrieved on: 
Tuesday, February 28, 2023
Spectrum disorder, Total permanent disability insurance, Collection, Disease, Self-assessment, Biomarker, Research, Algorithm, Patient, Rare disease, Digital, GMG, Fatigue, Alexion, Communication, Pharmaceutical industry, Medical imaging, NMOSD, Neurology

The programs will leverage assets, methodologies and expertise built by Ad Scientiam over the past five years and are supported by Alexion, AstraZeneca Rare Disease.

Key Points: 
  • The programs will leverage assets, methodologies and expertise built by Ad Scientiam over the past five years and are supported by Alexion, AstraZeneca Rare Disease.
  • gMG and NMOSD are chronic severe diseases in which progression is complex and critical to monitor.
  • Digital biomarkers are patient-generated physiological and behavioral measures that are collected from digital devices like smartphones and processed by algorithms.
  • Scoping phases have been conducted for both programs to identify clinically meaningful digital biomarkers to monitor patients living with NMOSD or gMG.